Profile data is unavailable for this security.
About the company
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- Revenue in USD (TTM)313.79m
- Net income in USD28.76m
- Incorporated1991
- Employees407.00
- LocationMannKind Corp1 Casper StreetDANBURY 06810United StatesUSA
- Phone+1 (818) 661-5000
- Fax+1 (302) 636-5454
- Websitehttps://mannkindcorp.com/
More ▼
Mergers & acquisitions
| Acquired company | MNKD:NMQ since announced | Transaction value |
|---|---|---|
| scPharmaceuticals Inc | 37.71% | 340.86m |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics Inc | 83.98m | -264.46m | 1.62bn | 317.00 | -- | 2.97 | -- | 19.26 | -3.04 | -3.04 | 0.969 | 5.29 | 0.1237 | -- | -- | 264,921.10 | -38.96 | -36.56 | -45.01 | -43.34 | -- | -- | -314.90 | -316.85 | -- | -- | 0.00 | -- | 53.95 | 36.35 | -36.62 | -- | 25.19 | -- |
| Agios Pharmaceuticals Inc | 44.79m | -401.27m | 1.64bn | 486.00 | -- | 1.27 | -- | 36.54 | -6.96 | -6.96 | 0.7768 | 22.04 | 0.0282 | 0.1959 | 11.00 | 92,162.55 | -25.26 | -10.38 | -26.90 | -11.09 | 87.22 | -- | -895.86 | -768.40 | 13.39 | -- | 0.00 | -- | 36.07 | -- | 291.35 | -- | -32.66 | -- |
| Rapt Therapeutics Inc | 0.00 | -105.64m | 1.67bn | 60.00 | -- | 6.41 | -- | -- | -11.08 | -11.08 | 0.00 | 9.02 | 0.00 | -- | -- | 0.00 | -77.05 | -49.22 | -84.35 | -54.31 | -- | -- | -- | -4,359.44 | -- | -- | 0.00 | -- | -- | -- | -11.19 | -- | -32.77 | -- |
| Sionna Therapeutics Inc | 0.00 | -70.68m | 1.68bn | 48.00 | -- | 5.20 | -- | -- | -1.61 | -1.61 | 0.00 | 7.23 | 0.00 | -- | -- | 0.00 | -26.35 | -- | -27.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.52 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 599.82m | -8.78m | 1.69bn | 580.00 | -- | -- | -- | 2.81 | -0.0473 | -0.0473 | 2.78 | -1.84 | 1.28 | 2.10 | 7.32 | 1,034,166.00 | -1.87 | -40.01 | -2.96 | -53.68 | 97.39 | 97.34 | -1.46 | -75.69 | 1.83 | 0.9698 | 2.35 | -- | 36.00 | 55.97 | 60.77 | -- | 26.79 | -- |
| Ardelyx Inc | 398.23m | -56.55m | 1.70bn | 395.00 | -- | 11.04 | -- | 4.28 | -0.2364 | -0.2364 | 1.66 | 0.635 | 0.9326 | 2.57 | 6.14 | 1,008,187.00 | -13.24 | -35.80 | -16.15 | -45.22 | 88.21 | 86.06 | -14.20 | -80.49 | 4.11 | -2.07 | 0.5671 | -- | 168.06 | 129.14 | 40.76 | -- | 25.48 | -- |
| Pharvaris NV | 0.00 | -194.32m | 1.70bn | 108.00 | -- | 4.66 | -- | -- | -3.46 | -3.46 | 0.00 | 5.71 | 0.00 | -- | -- | 0.00 | -50.22 | -36.71 | -53.72 | -38.87 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -33.06 | -- | 109.04 | -- |
| Tango Therapeutics Inc | 66.50m | -100.52m | 1.71bn | 155.00 | -- | 8.83 | -- | 25.64 | -0.9208 | -0.9208 | 0.593 | 1.43 | 0.2364 | -- | -- | 429,038.70 | -35.74 | -- | -39.69 | -- | -- | -- | -151.15 | -283.69 | -- | -- | 0.00 | -- | 15.17 | -- | -28.07 | -- | -- | -- |
| MBX Biosciences Inc | 0.00 | -80.50m | 1.71bn | 43.00 | -- | 4.38 | -- | -- | -3.39 | -3.39 | 0.00 | 8.67 | 0.00 | -- | -- | 0.00 | -23.59 | -- | -24.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -90.16 | -- | -- | -- |
| MannKind Corp | 313.79m | 28.76m | 1.73bn | 407.00 | 60.79 | -- | 46.51 | 5.51 | 0.0926 | 0.0926 | 1.02 | -0.1451 | 0.6545 | 2.52 | 17.64 | 770,975.40 | 6.00 | -14.54 | 7.40 | -19.49 | 78.49 | 65.89 | 9.16 | -28.96 | 3.04 | 2.68 | 1.14 | -- | 43.50 | 35.27 | 331.09 | -- | 30.46 | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.73bn | 263.00 | -- | 5.48 | -- | 12.89 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Galecto Inc | 0.00 | -15.84m | 1.81bn | 5.00 | -- | 5.98 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| Stoke Therapeutics Inc | 205.63m | 40.57m | 1.82bn | 128.00 | 48.32 | 5.71 | 42.90 | 8.86 | 0.66 | 0.66 | 3.52 | 5.59 | 0.6293 | -- | 35.68 | 1,606,500.00 | 12.41 | -34.04 | 14.44 | -37.36 | -- | -- | 19.73 | -749.56 | -- | -- | 0.00 | -- | 316.34 | -- | 15.01 | -- | -34.11 | -- |
| Syndax Pharmaceuticals Inc | 111.55m | -311.58m | 1.84bn | 270.00 | -- | 15.92 | -- | 16.47 | -3.61 | -3.61 | 1.29 | 1.33 | 0.2282 | -- | 4.67 | 413,151.80 | -63.74 | -32.19 | -77.50 | -35.11 | 95.44 | -- | -279.31 | -440.06 | 4.42 | -87.92 | 0.7487 | -- | -- | 73.25 | -52.25 | -- | -- | -- |
| Semnur Pharmaceuticals Inc | 0.00 | -1.46m | 1.84bn | -- | -- | -- | -- | -- | -0.4678 | -0.4678 | 0.00 | -4.05 | 0.00 | -- | -- | -- | -5.54 | -- | -7.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -126.45 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to MannKind Corp's reporting currency: US Dollar USD
29.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 23.34m | 7.60% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 15.42m | 5.02% |
| Rubric Capital Management LPas of 30 Sep 2025 | 11.41m | 3.72% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 10.74m | 3.50% |
| Geode Capital Management LLCas of 30 Sep 2025 | 7.39m | 2.41% |
| Nitorum Capital LPas of 30 Sep 2025 | 6.56m | 2.14% |
| UBS Securities LLCas of 31 Dec 2025 | 5.05m | 1.65% |
| Avoro Capital Advisor LLCas of 30 Sep 2025 | 4.47m | 1.46% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 3.79m | 1.24% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 3.32m | 1.08% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
